Enlivex Therapeutics Ltd

Research Enlivex Therapeutics Ltd (ENLV) on Bullrun: market cap USD 138.80M, P/E 0.0. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerENLV
• ExchangeNASDAQ
• CountryIsrael
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 138.80M
• P/E0.0
• Financial periodFY2025
• Net incomeUSD 1.24B
• Free cash flow-USD 10.48M

Valuation Snapshot

latest market cap is USD 138.80M; P/E is 0.0.

About Enlivex Therapeutics Ltd

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ);

Frequently asked questions

What is Enlivex Therapeutics Ltd's market cap?

Enlivex Therapeutics Ltd's market capitalization is USD 138.80M.

What is Enlivex Therapeutics Ltd's P/E ratio?

Enlivex Therapeutics Ltd's price-to-earnings (P/E) ratio is 0.0.

What does Enlivex Therapeutics Ltd do?

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.